-
Something wrong with this record ?
Surgical options after Fontan failure
JP. van Melle, D. Wolff, J. Hörer, E. Belli, B. Meyns, M. Padalino, H. Lindberg, JP. Jacobs, IP. Mattila, H. Berggren, RM. Berger, R. Prêtre, MG. Hazekamp, M. Helvind, M. Nosál, T. Tlaskal, J. Rubay, S. Lazarov, A. Kadner, V. Hraska, J. Fragata,...
Language English Country England, Great Britain
Document type Journal Article, Multicenter Study, Observational Study
NLK
ProQuest Central
from 1996-01-01 to 3 months ago
Health & Medicine (ProQuest)
from 1996-01-01 to 3 months ago
- MeSH
- Time Factors MeSH
- Child MeSH
- Adult MeSH
- Fontan Procedure adverse effects mortality MeSH
- Kaplan-Meier Estimate MeSH
- Infant MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Treatment Failure MeSH
- Postoperative Complications diagnosis mortality physiopathology surgery MeSH
- Child, Preschool MeSH
- Proportional Hazards Models MeSH
- Retrospective Studies MeSH
- Risk Factors MeSH
- Heart Transplantation * adverse effects mortality MeSH
- Heart Defects, Congenital diagnosis mortality surgery MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Infant MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Observational Study MeSH
- Geographicals
- Europe MeSH
OBJECTIVE: The objective of this European multicenter study was to report surgical outcomes of Fontan takedown, Fontan conversion and heart transplantation (HTX) for failing Fontan patients in terms of all-cause mortality and (re-)HTX. METHODS: A retrospective international study was conducted by the European Congenital Heart Surgeons Association among 22 member centres. Outcome of surgery to address failing Fontan was collected in 225 patients among which were patients with Fontan takedown (n=38; 17%), Fontan conversion (n=137; 61%) or HTX (n=50; 22%). RESULTS: The most prevalent indication for failing Fontan surgery was arrhythmia (43.6%), but indications differed across the surgical groups (p<0.001). Fontan takedown was mostly performed in the early postoperative phase after Fontan completion, while Fontan conversion and HTX were mainly treatment options for late failure. Early (30 days) mortality was high for Fontan takedown (ie, 26%). Median follow-up was 5.9 years (range 0-23.7 years). The combined end point mortality/HTX was reached in 44.7% of the Fontan takedown patients, in 26.3% of the Fontan conversion patients and in 34.0% of the HTX patients, respectively (log rank p=0.08). Survival analysis showed no difference between Fontan conversion and HTX (p=0.13), but their ventricular function differed significantly. In patients who underwent Fontan conversion or HTX ventricular systolic dysfunction appeared to be the strongest predictor of mortality or (re-)HTX. Patients with valveless atriopulmonary connection (APC) take more advantage of Fontan conversion than patients with a valve-containing APC (p=0.04). CONCLUSIONS: Takedown surgery for failing Fontan is mostly performed in the early postoperative phase, with a high risk of mortality. There is no difference in survival after Fontan conversion or HTX.
Children's Heart Centre The Queen Silvia Children's Hospital Gothenburg Sweden
Clinic for Cardiovascular Surgery University Hospital Zurich Zurich Switzerland
Department of Cardiac Surgery Catholic University Leuven Leuven Belgium
Department of Cardio Thoracic Surgery University Hospital of Copenhagen Copenhagen Denmark
Department of Cardiothoracic Surgery Hospital de Santa Marta Lisbon Portugal
Department of Congenital and Paediatric Cardiac Surgery and Cardiology Riuniti Hospital Ancona Italy
Department of Congenital Heart Disease Centre Chirurgical Marie Lannelongue Paris France
Division of Cardiac Surgery Cliniques Universitaires Saint Luc Brussels Belgium
German Pediatric Heart Centre Asklepios Clinic Sankt Augustin Sankt Augustin Germany
Hospital for Children and Adolescents University of Helsinki Helsinki Finland
National Heart Hospital Sofia Sofia Bulgaria
Technical University German Heart Center Munich Munich Germany
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17031790
- 003
- CZ-PrNML
- 005
- 20171031102847.0
- 007
- ta
- 008
- 171025s2016 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1136/heartjnl-2015-309235 $2 doi
- 035 __
- $a (PubMed)27076374
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a van Melle, Joost P $u Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
- 245 10
- $a Surgical options after Fontan failure / $c JP. van Melle, D. Wolff, J. Hörer, E. Belli, B. Meyns, M. Padalino, H. Lindberg, JP. Jacobs, IP. Mattila, H. Berggren, RM. Berger, R. Prêtre, MG. Hazekamp, M. Helvind, M. Nosál, T. Tlaskal, J. Rubay, S. Lazarov, A. Kadner, V. Hraska, J. Fragata, M. Pozzi, G. Sarris, G. Michielon, D. di Carlo, T. Ebels,
- 520 9_
- $a OBJECTIVE: The objective of this European multicenter study was to report surgical outcomes of Fontan takedown, Fontan conversion and heart transplantation (HTX) for failing Fontan patients in terms of all-cause mortality and (re-)HTX. METHODS: A retrospective international study was conducted by the European Congenital Heart Surgeons Association among 22 member centres. Outcome of surgery to address failing Fontan was collected in 225 patients among which were patients with Fontan takedown (n=38; 17%), Fontan conversion (n=137; 61%) or HTX (n=50; 22%). RESULTS: The most prevalent indication for failing Fontan surgery was arrhythmia (43.6%), but indications differed across the surgical groups (p<0.001). Fontan takedown was mostly performed in the early postoperative phase after Fontan completion, while Fontan conversion and HTX were mainly treatment options for late failure. Early (30 days) mortality was high for Fontan takedown (ie, 26%). Median follow-up was 5.9 years (range 0-23.7 years). The combined end point mortality/HTX was reached in 44.7% of the Fontan takedown patients, in 26.3% of the Fontan conversion patients and in 34.0% of the HTX patients, respectively (log rank p=0.08). Survival analysis showed no difference between Fontan conversion and HTX (p=0.13), but their ventricular function differed significantly. In patients who underwent Fontan conversion or HTX ventricular systolic dysfunction appeared to be the strongest predictor of mortality or (re-)HTX. Patients with valveless atriopulmonary connection (APC) take more advantage of Fontan conversion than patients with a valve-containing APC (p=0.04). CONCLUSIONS: Takedown surgery for failing Fontan is mostly performed in the early postoperative phase, with a high risk of mortality. There is no difference in survival after Fontan conversion or HTX.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a Evropa $7 D005060
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a Fontanova operace $x škodlivé účinky $x mortalita $7 D018729
- 650 _2
- $a vrozené srdeční vady $x diagnóza $x mortalita $x chirurgie $7 D006330
- 650 12
- $a transplantace srdce $x škodlivé účinky $x mortalita $7 D016027
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a pooperační komplikace $x diagnóza $x mortalita $x patofyziologie $x chirurgie $7 D011183
- 650 _2
- $a proporcionální rizikové modely $7 D016016
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a neúspěšná terapie $7 D017211
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Wolff, Djoeke $u Department of Pediatric Cardiology, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
- 700 1_
- $a Hörer, Jürgen $u Technical University, German Heart Center Munich, Munich, Germany.
- 700 1_
- $a Belli, Emre $u Department of Congenital Heart Disease, Centre Chirurgical Marie Lannelongue, Paris, France.
- 700 1_
- $a Meyns, Bart $u Department of Cardiac Surgery, Catholic University Leuven, Leuven, Belgium.
- 700 1_
- $a Padalino, Massimo $u Pediatric and Congenital Cardiovascular Surgery Unit, Department of Cardiac Thoracic and Vascular Sciences, University of Padova, Padua, Italy.
- 700 1_
- $a Lindberg, Harald $u Department of Thoracic and Cardiovascular Surgery, Rikshospitalet, Oslo University Hospital, Oslo, Norway.
- 700 1_
- $a Jacobs, Jeffrey P $u Johns Hopkins All Children's Heart Institute, All Children's Hospital and Florida Hospital for Children, Saint Petersburg, Tampa, and Orlando, Florida, USA Johns Hopkins University, Baltimore, Maryland, USA.
- 700 1_
- $a Mattila, Ilkka P $u Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland.
- 700 1_
- $a Berggren, Håkan $u Children's Heart Centre, The Queen Silvia Children's Hospital, Gothenburg, Sweden.
- 700 1_
- $a Berger, Rolf M F $u Department of Pediatric Cardiology, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
- 700 1_
- $a Prêtre, Rene $u Clinic for Cardiovascular Surgery, University Hospital Zurich, Zurich, Switzerland.
- 700 1_
- $a Hazekamp, Mark G $u Leiden University Medical Center, Leiden, The Netherlands Academic Medical Center, Amsterdam, The Netherlands.
- 700 1_
- $a Helvind, Morten $u Department of Cardio-Thoracic Surgery, University Hospital of Copenhagen, Copenhagen, Denmark.
- 700 1_
- $a Nosál, Matej $u National Institute of Cardiovascular Disease, Children's Heart Centre Slovak Republic, Bratislava, Slovakia.
- 700 1_
- $a Tlaskal, Tomas $u Department of Pediatric Cardiac Surgery, Children's Heart Center, Motol University Hospital, Prague, Czech Republic.
- 700 1_
- $a Rubay, Jean $u Division of Cardiac Surgery, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
- 700 1_
- $a Lazarov, Stojan $u National Heart Hospital Sofia, Sofia, Bulgaria.
- 700 1_
- $a Kadner, Alexander $u Department of Cardiovascular Surgery, Center for Congenital Heart Surgery, University Hospital Bern, Bern, Switzerland.
- 700 1_
- $a Hraska, Viktor $u German Pediatric Heart Centre, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany.
- 700 1_
- $a Fragata, José $u Department of Cardiothoracic Surgery, Hospital de Santa Marta, Lisbon, Portugal.
- 700 1_
- $a Pozzi, Marco $u Department of Congenital and Paediatric Cardiac Surgery and Cardiology, Riuniti Hospital, Ancona, Italy.
- 700 1_
- $a Sarris, George $u Athens Heart Surgery Institute, Athens, Greece Department of Pediatric, Congenital Heart Surgery at IASO Children's Hospital, Athens, Greece.
- 700 1_
- $a Michielon, Guido $u Department of cardiothoracic surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
- 700 1_
- $a di Carlo, Duccio $u Dipartimento Medico-Chirurgico di Cardiologia Pediatrica, Ospedale Pediatrico Bambino Gesù, Roma, Italia.
- 700 1_
- $a Ebels, Tjark $u Department of cardiothoracic surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
- 773 0_
- $w MED00002003 $t Heart (British Cardiac Society) $x 1468-201X $g Roč. 102, č. 14 (2016), s. 1127-33
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27076374 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20171031102937 $b ABA008
- 999 __
- $a ok $b bmc $g 1255383 $s 992817
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 102 $c 14 $d 1127-33 $e 20160413 $i 1468-201X $m Heart $n Heart $x MED00002003
- LZP __
- $a Pubmed-20171025
